Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (391-400 of 755) with videos related to

Pageof 76
Sort By:
Arthritis and Rheumatism|July 11, 2012
Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot studyRajeev Saggar, D Khanna, S Shapiro, et al.
Rheumatology (Oxford, England)|February 11, 2015
Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosisBeth Wallace, Suzanne Kafaja, Daniel E Furst, et al.
Clinical and Experimental Immunology|June 10, 2010
Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma)S P Atamas, I G Luzina, J Ingels, et al.
The Journal of Rheumatology|June 3, 2015
Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life StudySarah D Mills, Rina S Fox, Erin L Merz, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 18, 2015
Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-AnalysisSarah S Thomas, Nabeel Borazan, Nashla Barroso, et al.
Biopharmaceutics & Drug Disposition|October 1, 1983
Biliary secretion of sulindac and metabolites in manM R Dobrinska, D E Furst, T Spiegel, et al.
Annals of the Rheumatic Diseases|August 6, 2008
Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability studyP J Mease, K Hobbs, A Chalmers, et al.
Blood|September 28, 2002
Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answerNathalie C Lambert, Y M Dennis Lo, Timothy D Erickson, et al.
Arthritis Research & Therapy|February 4, 2014
Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one yearJonathan Kay, Olga Morgacheva, Susan P Messing, et al.
Pageof 76

Showing results (391-400 of 755) with videos related to

Sort By:
Pageof 76
Arthritis and Rheumatism|July 11, 2012
Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot studyRajeev Saggar, D Khanna, S Shapiro, et al.
Rheumatology (Oxford, England)|February 11, 2015
Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosisBeth Wallace, Suzanne Kafaja, Daniel E Furst, et al.
Clinical and Experimental Immunology|June 10, 2010
Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma)S P Atamas, I G Luzina, J Ingels, et al.
The Journal of Rheumatology|June 3, 2015
Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life StudySarah D Mills, Rina S Fox, Erin L Merz, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 18, 2015
Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-AnalysisSarah S Thomas, Nabeel Borazan, Nashla Barroso, et al.
Biopharmaceutics & Drug Disposition|October 1, 1983
Biliary secretion of sulindac and metabolites in manM R Dobrinska, D E Furst, T Spiegel, et al.
Annals of the Rheumatic Diseases|August 6, 2008
Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability studyP J Mease, K Hobbs, A Chalmers, et al.
Blood|September 28, 2002
Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answerNathalie C Lambert, Y M Dennis Lo, Timothy D Erickson, et al.
Arthritis Research & Therapy|February 4, 2014
Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one yearJonathan Kay, Olga Morgacheva, Susan P Messing, et al.
Pageof 76